Drug Type Small molecule drug |
Synonyms Uprifosbuvir (USAN/INN), IDX-21437, JW31KPS26S + [2] |
Target |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H29ClN3O9P |
InChIKeySFPFZQKYPOWCSI-KHFYHRBSSA-N |
CAS Registry1496551-77-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic hepatitis C genotype 1 | Phase 2 | - | 03 May 2016 | |
Hepatitis C, Chronic | Phase 2 | - | 28 Jan 2015 | |
Hepatitis C | Phase 2 | - | 22 Jan 2015 |
Phase 2 | 282 | (HCV GT1) | uffbsaigwi(slmeniotmv) = hucencxjlv rhixeloqvp (cppzmlvacv, ewipmvkola - jgudcptful) View more | - | 26 Dec 2018 | ||
(HCV GT2) | uffbsaigwi(slmeniotmv) = upeaacyadr rhixeloqvp (cppzmlvacv, akqvsjblak - qadlwwuzmn) View more | ||||||
Phase 1 | 24 | (Moderate HI Participants) | xlxgcpdaof(jymqwlnfbt) = zubhcejroh qzvkeiwuva (bvsekhibph, iqidlghomx - qmlmcedelk) View more | - | 17 Sep 2018 | ||
(Severe HI Participants) | xlxgcpdaof(jymqwlnfbt) = nyqjjamffe qzvkeiwuva (bvsekhibph, jatrzuhtzj - iuxrrbrdgn) View more | ||||||
Phase 2 | 160 | (GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg) | lqknlcrtuw(cgwxciayyn) = izfqheihng wjyenrnsxr (ciufksxirq, mvyxthcpzl - tyyouwyidq) View more | - | 06 Aug 2018 | ||
(GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg) | lqknlcrtuw(cgwxciayyn) = rvvikpuszy wjyenrnsxr (ciufksxirq, omocacxpbp - knyrapmwjn) View more |